NewAmsterdam Pharma secures positive CHMP opinion for obicetrapib
NewAmsterdam Pharma reported strong Q2 results including a positive European regulatory opinion for obicetrapib, signaling significant progress for its late-stage CVD pipeline.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day